Predictive Disease Analytics Market Trends Analysis Report 2025-2030: AI and Analytics Tools Gain Traction as Healthcare Systems Seek Cost Efficiency and Better Outcomes
Predictive Disease Analytics Market
Dublin, May 22, 2025 (GLOBE NEWSWIRE) -- The "Predictive Disease Analytics Market Size, Share & Trends Analysis Report by Component (Hardware, Software & Services), Deployment (On-premise, Cloud-based), End Use, Region, with Growth Forecasts, 2025-2030" report has been added to ResearchAndMarkets.com's offering.The Predictive Disease Analytics Market was valued at USD 3.0 Billion in 2024, and is projected to reach USD 10.2 Billion by 2030, rising at a CAGR of 22.70%
Predictive disease analytics refers to software solutions used by healthcare organizations, hospitals, and physicians to analyze and process patient data in order to provide data-driven, high-quality care, precise diagnostics, and individualized treatments. Predictive analytics is an advanced method to enhance patient outcomes in healthcare.
Additionally, predictive analytics solutions are used by healthcare providers to comprehend disease prevalence, disease management, risk management & trajectories, and to provide suitable medical care to patients for optimal outcomes. Healthcare providers use it to evaluate the risk rate to an individual's health as well as predict future outcomes in preparation. Its use at various levels to avoid unnecessary expenditure had also increased the utilization of this technology, which is anticipated to continue throughout the forecast period. As a result, the global predictive disease analytics market is expected to grow.Predictive analytics has played a significant part in combating COVID-19 problems, decreasing the incidence of poor outcomes for patients, and addressing resource management during the crisis. The massive amount of patient data produced during the outbreak not only provided analytics firms and the healthcare sector with data to properly analyze disease spread, but it also aided in resource allocation. Several institutions, including hospitals, was using predictive analytics to determine the probability of a patient developing severe symptoms, the trajectory of their infection/disease, and several other parameters. For instance, in 2020, researchers at the Cleveland Clinic in the U. S. created an automated analytics model that predicted an individual's chance of testing positive. Hence, propelling the market growth.The global market is expanding rapidly as a result of the increasing burden of chronic diseases, the emergence of personalized and evidence-based medicine, the growing need for increased efficiency in the healthcare sector, and the growing demand to reduce healthcare costs by eliminating unnecessary costs. As per the center for disease control, six out of every ten Americans have at least one chronic illness, such as heart disease or stroke, cancer, or diabetes. Hence, it will increase the product demand and further boost the market growth.Another important reason driving market growth is the use of evidence-based medicine to provide the right kind of treatment to the right patient. The utilization of Electronic Health Records (EHRs) for patient records has increased in recent years, with adoption of EHRs in the case of office-based doctors increasing from 42% in 2008 to nearly 88% in 2021 in the U. S. Healthcare predictive analytics makes use of EHRs to recommend the best course of action in the event of a medical treatment or medication. This not only greatly reduces patient costs but also leads to improved outcomes. The adoption of electronic health systems, analytics tools, and artificial intelligence (AI) are expected to drive market development. The expense of healthcare has risen over the years owing to the increasing burden of chronic diseases on a global level.The companies in the predictive disease analytics market are continuously expanding their product and services portfolio to accelerate the development of the product. For instance, in June 2022, Engagys LLC, a Health Consultant Company, announced the debut of a new affordable subscription service for healthcare systems, health plans, & healthcare technology leaders. Executive Advisory Services is intended to provide healthcare customer engagement practitioners with practical and actionable guidance, insights, and best practices that they can put to use immediately. This is expected to strengthen the company's position in predictive analytics solution and further boost the market growth.Predictive Disease Analytics Market Report Highlights
Cloud-based solutions are anticipated to have the highest CAGR during the forecast period. The ease of storage, inexpensive capital requirements, increased flexibility, and efficiency are attributed to its development.
On the basis of end user, payer segment dominated the market in 2023.Payers, such as insurance firms, health plan sponsors, as well as other third-party payers, are among the primary beneficiaries of predictive analytics in healthcare settings. Thus, boosting the segment growth.
Due to the rising prevalence of chronic diseases, greater awareness of preventive health and rising percentage of geriatric population in North America, the region had the largest market share.
Why Should You Buy This Report?
Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
Competitive Landscape: Explore the market presence of key players.
Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
Key Attributes:
Report Attribute
Details
No. of Pages
80
Forecast Period
2024 - 2030
Estimated Market Value (USD) in 2024
$3 Billion
Forecasted Market Value (USD) by 2030
$10.2 Billion
Compound Annual Growth Rate
22.7%
Regions Covered
Global
Predictive Disease Analytics Market Variables, Trends & Scope
Market Lineage Outlook
Parent market outlook
Related/ancillary market outlook
Market Driver Analysis
Rise in government initiatives and an increasing amount of money being invested in the healthcare industry
Technological advancements in AI and machine learning
Increasing prevalence of chronic diseases
Growing shift towards personalized medicine
Market Restraint Analysis
Growing data privacy concerns
Lack of skilled professionals
High implementation cost
Companies Featured
Oracle
Cerner Corporation
IBM
SAS
Allscripts Healthcare Solutions Inc.
MedeAnalytics, Inc.
Health Catalyst.
Apixio Inc
GE Healthcare (a division of General Electric Company)
Siemens Healthineers
For more information about this report visit https://www.researchandmarkets.com/r/uu9aic
About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
Predictive Disease Analytics Market
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
36 minutes ago
- Yahoo
NHS set for boost of up to £30bn as other budgets feel squeeze
The NHS is expected to receive a funding boost of up to £30 billion in the spending review next week at the expense of other public services. The Department of Health is set to be handed a 2.8% annual increase in its day-to-day budget over a three-year period. The cash injection, which amounts to a rise of about £30 billion by 2028, or £17 billion in real terms, will see other areas including police and councils squeezed, The Times newspaper reported. Sir Keir Starmer has pledged to ensure that by the next election 92% of patients in England waiting for planned treatment are seen within 18 weeks of being referred. Latest NHS data suggests around 60% of people are currently seen in this time and figures released last month showed the overall number of patients on waiting lists had risen slightly from 6.24 million to 6.25 million. Chancellor Rachel Reeves has acknowledged that she had been forced to turn down requests for funding in a sign of the behind-the-scenes wrangling over her spending review. She insisted the blame for the tight economic situation lay with the Conservatives rather than her rigid rules on borrowing and spending. The Chancellor said despite a £190 billion increase in funding over the spending review period 'not every department will get everything that they want next week and I have had to say no to things that I want to do too'. On top of the increase in day-to-day spending, funded in part by the tax hikes Ms Reeves set out in her budget, looser borrowing rules will help support a £113 billion investment package. Economists have warned the Chancellor faces 'unavoidably' tough choices when she sets out departmental spending plans on June 11. The Institute for Fiscal Studies (IFS) think tank said defence and the NHS will dominate the review, raising the prospect of cuts to other unprotected departments.
Yahoo
an hour ago
- Yahoo
Novo Nordisk Stock: Is It Still a Smart Buy?
This one-time weight-loss drug leader has suffered several setbacks lately. It isn't wise to count out this veteran pharmaceutical company, however. 10 stocks we like better than Novo Nordisk › Much like the long-term users of its most popular product, Novo Nordisk's (NYSE: NVO) stock has slimmed down considerably of late. Share prices of the company, which developed and sells weight loss drug Wegovy, have fallen nearly 18% in price since the start of this year. Popularity attracts competition, and investors are growing concerned that the Danish pharmaceutical giant won't be able to compete. I've been a Novo Nordisk bull for quite some time now, and I wouldn't be as spooked by the situation. Here's why. Novo Nordisk got a two-year-plus head start in the white-hot obesity drugs market, when Wegovy became the first GLP-1 drug specifically approved by the Food and Drug Administration (FDA) for that indication in mid-2021. Novo Nordisk's Ozempic was first, but it was used off-label as a weight-loss drug, and had only initially been approved as a diabetes treatment and kidney disease treatment. It's easy to believe in a company when it's riding high and unopposed. But late in 2023, a new entrant was approved -- mighty American pharmaceutical company Eli Lilly (NYSE: LLY) with its own GLP-1 treatment, Zepbound -- giving Novo Nordisk one of the strongest competitors imaginable. Almost certainly, this won't continue to be a two-car race for long. Other companies, both large and small, in the healthcare field are pushing hard to develop their own obesity drugs, with varying degrees of success. Eli Lilly alone is an intimidating presence. A mainstay on the American pharmaceutical scene, it's grown to a massive size, to the point where it's the most valuable pharmaceutical company in the world by market cap. It can leverage its vast resources to develop and market any kind of medicine it wants, and in the obesity segment, it was already nearly there with Zepbound's FDA-approved-for-diabetes sibling drug, Mounjaro. Since then, it seems Zepbound has carved out a significant market share from Wegovy. Precise figures are hard to come by, but according to a Goldman Sachs analysis recently reported by Barron's, Novo Nordisk is clinging to a 51% share of the roughly $28 billion market. Eli Lilly holds the rest. Like other pharmaceutical industry pundits, Goldman Sachs is predicting that once other obesity drugs are developed successfully and approved, the market will fragment. That's a wholly believable prediction given the zeal and urgency behind many of those efforts. Meanwhile, Novo Nordisk has taken a series of competitive blows that reduced its lead. A shortage of semaglutide -- the main ingredient of Wegovy -- led the FDA to allow compounding pharmacies to make copies of the molecule, essentially producing new competition. Although the shortage is officially over, it showed that Novo Nordisk would be vulnerable if such a situation reoccurred. Another of the numerous fresh setbacks was a head-to-head clinical trial conducted by Eli Lilly, pitting Zepbound against Wegovy. Last December, the results of the study indicated notably more significant weight loss for participants using Wegovy. One internal development also dented investor sentiment on Novo Nordisk, and that was the company's announcement in mid-May that long-serving CEO Lars Fruergaard Jørgensen was stepping down. When enterprises are humming along pleasantly, they rarely experience a top leader's departure. Novo Nordisk isn't just absorbing hurtful blows, though; it's been busy shoring up its defenses. As 2024 came to a close, it scooped up contract drug manufacturer Catalent, bringing Wegovy production more under its direct control. That $16.5 billion deal wasn't cheap by any yardstick, but if the new asset is managed well, it should be more than worth the cost ultimately. Novo Nordisk is also keeping up the pace with its own development activities, attempting to succeed with new medications and/or other indications for Wegovy. Its next-generation obesity treatment CagriSema was essentially a flop. However, the company has already had success winning FDA approval for the versatile Wegovy to treat liver disorder metabolic dysfunction-associated steatohepatitis (MASH), and it's developing the drug for a clutch of other ailments. It also has other medications for different disorders in its pipeline. Meanwhile, a score of researchers modeling the future of the obesity market feel that sales of such drugs will blast through the roof. Projections vary, but a typical one is the latest from Morgan Stanley. In May, the veteran investment bank upped its estimate for the market's peak (predicted to occur in 2035) to $150 billion, well up from its previous assumption of $105 billion. The former number is more than 6 times the $24 billion estimated sales of 2024. The very encouraging news for Novo Nordisk bulls like myself is that even if the market gets highly fragmented with numerous competing products and loses significantly more share -- unlikely, given its first-mover prominence and the strength of the Wegovy brand name -- it'll still be a player in a huge market. Yes, competition can be tough. There are a lot of prizes in this game, and more players are entering it. But I think this original player will manage to hold on and thrive, and I continue to consider Novo Nordisk stock a buy. Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,538!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $869,841!* Now, it's worth noting Stock Advisor's total average return is 789% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Goldman Sachs Group. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. Novo Nordisk Stock: Is It Still a Smart Buy? was originally published by The Motley Fool
Yahoo
3 hours ago
- Yahoo
NHS app to become default source for appointments, screenings and test results
The NHS app will become the default method of communication for patients seeking appointment reminders, screening invitations and test results as part of a major investment. Millions more people will receive personal health information directly to their smartphones within the next three years in a move that is expected to save the health service £200 million, the Department of Health and Social Care said. It will also avoid the need for at least 50 million NHS letters being sent by post each year, with the Health Secretary likening the shift from analogue to digital to 'online banking or ordering a takeaway'. The £50 million investment will see 270 million messages sent through the NHS app this year, an increase of 70 million on the previous financial year. Push notifications will provide appointment reminders to patients to try to reduce the risk of no attendance, with around eight million missed appointments in elective care missed in 2023/24. More than 11 million people in the UK currently log into the NHS app every month, while almost 20 million are opted in to receive healthcare messages from the app. Where app messaging is not available, particularly for elderly patients without smartphones, communications will be sent via text message and then by letter as a last resort and phone lines will be freed up. It is hoped the changes will give patients better access to manage their healthcare journey and make informed decisions about their care. NHS app services, which were launched in December 2018, are now used in 87% of hospitals across England. Last month, NHS England announced millions of patients would be able to get 'Amazon-style' tracking updates on their prescriptions through the app, to check if their medicines are ready to collect or have been despatched for delivery. Health Secretary Wes Streeting said: 'People are living increasingly busy lives and want to access information about their health at the touch of a button, rather than having to wait weeks for letters that often arrive too late. 'This Government is bringing our analogue health service into the digital age, so that being a patient in the NHS is as convenient as online banking or ordering a takeaway. 'The NHS still spends hundreds of millions of pounds on stamps, printing, and envelopes. By modernising the health service, we can free up huge amounts of funding to reinvest in the front line. 'Through the investment and reform in our Plan for Change, we will make the NHS App the front door to the health service and put power in the hands of patients.' Rachel Power, chief executive of the Patient's Association, said: 'This major upgrade to the NHS App marks a significant step in modernising how patients receive information, from test results to screening invitations. 'This was a recommendation from our Digital Coalition and realises changes that patients have asked for. 'We welcome this investment and the ambition behind it. Success for any digital innovation will be the implementation of the Digital Inclusion Plan and working directly with patients and communities.'
